The table below shows Cullinan Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$175.75M
-$145.30M
-$134.28M
-$126.66M
-$43.43M
-$29.77M
Capital expenditure
$49.00K
$0.00
$208.00K
$1.13M
$0.00
$10.00K
Investing cash flow
$179.99M
-$136.31M
$35.81M
$248.97M
-$333.77M
-$5.42M
Dividends paid
-
-
-
-
-
CGEM operating cash flow (10-K history)
Cullinan Therapeutics, Inc. reported operating cash flow of -$175.75M for fiscal year 2025. That is down 21.0% from -$145.30M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$29.77M (FY 2020) to -$175.75M. Figures come from the company's audited annual reports as filed with the SEC.
